Last updated: February 20, 2026
Prochlorperazine is a typical antipsychotic medication also used as an antiemetic. It is primarily produced by generic manufacturers, with some brand-name options. The market is highly competitive, with suppliers spanning multiple regions, including North America, Europe, and Asia.
Major Manufacturers and Suppliers
Brand-Name Producers
- Compazine (Mallinckrodt Pharmaceuticals): Historically the primary brand in the U.S.
- Stemetil (GSK): Common in European markets.
Generic Manufacturers
- Teva Pharmaceuticals: Largest supplier globally, with extensive production capacity.
- Mylan (Subsidiary of Viatris): Supplies globally, with multiple manufacturing sites.
- Sandoz (Novartis): Known for high-quality generics.
- Sun Pharmaceutical Industries: Major Indian manufacturer supplying Asia, the Middle East, and Africa.
- Hikma Pharmaceuticals: Supported markets in Europe and North Africa.
- Zydus Cadila: Indian-based, offering competitive pricing and supply stability.
Regional Suppliers
- India: Major producers include Aurobindo Pharma, Cadila Healthcare, and Lupin.
- China: Several manufacturing units supply low-cost generics to global markets.
- Europe: GSK, Sandoz, and Teva maintain manufacturing sites adhering to EMA standards.
Manufacturing and Supply Landscape
| Supplier |
Manufacturing Regions |
GMP Certification |
Production Capacity |
Market Focus |
| Teva |
Israel, USA, Europe |
Yes |
High |
North America, Europe, global |
| Mylan (Viatris) |
India, USA |
Yes |
High |
Global |
| Sun Pharma |
India, USA |
Yes |
Moderate to high |
Asia, Africa, emerging markets |
| Sandoz |
Switzerland, Europe |
Yes |
High |
Europe, global |
| Aurobindo Pharma |
India, USA |
Yes |
High |
Asia, US, emerging markets |
| Zydus Cadila |
India |
Yes |
Moderate |
India, Africa, Asia |
Regulatory Considerations
All suppliers hold Good Manufacturing Practice (GMP) certifications recognized by agencies such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regional bodies. Production capacity is sufficient to meet global demand, with some suppliers offering contractual guarantees for supply continuity.
Market Access & Pricing
Prices for prochlorperazine vary based on region, formulation, and supplier. Generics dominate the market, with prices typically between $0.05 and $0.15 per tablet (depending on dosage and quantity). Brand-name products cost significantly more, often exceeding $1 per tablet.
Supply Chain Risks
Disruptions are linked to raw material shortages in active pharmaceutical ingredient (API) sourcing, regulatory delays, or manufacturing capacity constraints. Leading suppliers like Teva and Mylan have multiple plants to mitigate these risks.
Notable Trends
- Increasing API production capacity in India and China.
- Growing market share among Indian generics manufacturers.
- Supplier consolidation and alliances to ensure supply stability amid global demand fluctuations.
Conclusion
The supply of prochlorperazine is concentrated among large, GMP-certified generic firms. Teva, Mylan, and Sandoz are the primary global suppliers, supported by regional manufacturers in India and China. Market access relies on robust manufacturing infrastructure, regulatory compliance, and diversified supply chains.
Key Takeaways
- Prochlorperazine is primarily supplied by large global generic manufacturers and regional Asian producers.
- Teva and Mylan dominate the supply chain, with high manufacturing capacity.
- Prices for generics are low, but supply disruptions risk affecting availability.
- Regional suppliers in India, China, and Europe adhere to GMP standards.
- Market dynamics favor Indian manufacturers due to cost advantages and expanding capacities.
FAQs
1. Are there any major regulatory hurdles for suppliers of prochlorperazine?
Yes. Suppliers must meet GMP standards from agencies like the FDA or EMA. Regulatory approvals and compliance are critical for maintaining market access.
2. Which countries have the highest production of prochlorperazine API?
India and China are the primary API producers, stabilizing global API supply and driving down manufacturing costs.
3. How do pricing and supply stability compare among suppliers?
Pricing is generally consistent among large generic firms, with slight variations based on market region. Supply stability depends on capacity and raw material access; Teva and Mylan typically offer the most reliable supply.
4. Are there branded options besides generics?
Brand-name options like Compazine and Stemetil are available but are less common due to higher costs. The majority of the market relies on generics.
5. What trends influence future supplier stability?
Expansion of API production capacity in Asia, ongoing regulatory compliance, and supply chain diversification will impact the stability of prochlorperazine supply.
References
- U.S. Food and Drug Administration. (2022). Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- European Medicines Agency. (2022). Authorized medicines. https://www.ema.europa.eu/en/medicines
- IMS Health. (2021). Global Pharmaceutical Market Data Report.
- IQVIA. (2022). The Global Use of Medicines in 2022.
